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1. Introduction 
Behçet’s disease (BD) is a chronic, relapsing inflammatory disorder of unknown etiology 
and characterized by obstructive vasculitis. It can involve both the arteries and veins of 
almost any organ and characterized by recurrent oral and genital aphthous ulcers, ocular 
inflammation, and skin lesions. Behçet’s disease frequently involves the joints, the central 
nervous system, and the gastrointestinal tract as well. Behçet’s disease may be the best 
example of a disorder characterized mainly by its retinal vascular involvement, often with 
devastating results on the patient’s eyesight. 
First description of BD has been attributed to Hippocrates in the 5th century BC, in the 
“Third book of endemic diseases” (Nussenblatt, 2010). In 1937, Hulusi Behçet (1889-
1948), a Turkish dermatologist (Behçet, 1937), reported three patients with a triad of 
symptoms: recurrent intraocular inflammatory episodes with oral and genital 
ulcerations. 
2. Epidemiology 
2.1 Geographic and ethnic distribution 
Behçet’s disease is most common in the countries of the Eastern Mediterranean and in the 
Eastern rim of Asia, and is very frequently noted between 300 and 450 north latitude in 
Asian and European populations, which corresponds  to the old Silk Route used by traders 
from the East to Europe (Ohno, 1986). The exact incidence, prevalence, and family 
occurrence of the disease are not well known. The highest prevalence being 80-420 cases per 
100000 populations in Turkey has been reported (Azizlerli et al., 2003; Yazici, 1994; 
Yurdakul et al, 1988).  
2.2 Sex 
Many reports, mainly from Mediterranean basin and the Far East, have shown a 
preponderance of males to females in BD. Data have shown that men predominate in Japan 
(2:1), Lebanon (11:1), Greece (7.9:1), Egypt (5:1), Isreal (3:1), Turkey (3:1) and Iran (1.2:1), 
whereas women predominate in Germany (1:0,9), Brazil (1:0.7), and the United States (1:0.2) 
(Atmaca, 1989; Chajec & Fainaru, 1975; Hamdi & Abdalla, 1974; Mamo & Baghdassarian, 
1964;  Ozdal et al., 2002; Shimuzu, 1971).  
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Although BD effects primarily young adults more frequently between the second and fourth 
decade of life and is rarely seen in children, the onset can occur at any age from infants to 
the elderly (Ghate et al., 1999; Kone-Paut et al., 1998; Önder & Gürer, 2000; Tugal-Tutkun et 
al., 2004). 
2.4 Heredity  
Familial occurrence is seen in 8-18 % of Turkish patients with the disease (Onal et al., 2001), 
15% of Koreans, 13% of Jews, and 2.6% of Chinese (Fietta, 2005). Additionally, several 
familial cases (Dundar et al, 1985; Vaiopoulus et al., 1996; Villanueva et al., 1993) and a pair 
of monozygotic brothers (Hamuryudan et al., 1991) concordant for the disease have been 
reported, but no consistent inheritance pattern has been confirmed.  
3. Clinical features  
The diagnosis of BD is based firmly on the presence of a set of clinical findings.  The 
diagnostic criteria were first described in 1969 by Mason & Barnes (Mason & Barnes, 1969). 
Numerous sets of clinical criteria have been proposed for the diagnosis of BD (O’ Duffy, 
1974; Zhang, 1980).  
The most popular diagnostic system has been suggested by the Behçet’s Research 
Committee of Japan in 1974 (Behçet’s Disease Research Committee of Japan, 1974) (Table 1). 
The committee has revised the diagnostic criteria in 2003 (Kurokawa & Suzuki, 2004). The 
presence of ocular inflammation is given greater weight in the diagnosis in this system.  
 
Main symptoms: 1-Recurrent aphtous ulcers on oral mucosa; 2-Skin lesions (erythema 
nodosum, subcutaneous thrombophlebitis, follicular papules, acneiform papules, skin 
hypersensitivity); 3-Ocular lesions (anterior and/or posterior uveitis); 4-Genital ulcers 
Additional symptoms: 1-Arthritis without deformity or sclerosis; 2-Epididymitis; 3-
Gastrointestinal lesion (Ileocecal ulceration); 4-Vascular lesions; 5-Central nervous system 
lesions 
Criteria for diagnosis of disease types: 
Complete type: Four main symptoms 
Incomplete type: Three of the main symptoms, or two main symptoms and two 
additional symptoms; typical ocular lesion and another main symptom, or two additional 
symptoms 
BD suspected: Some main symptoms appear, but the case does not meet the criteria for 
the incomplete type;  typical additional symptom is recurrent or becomes more severe 
Special lesions: Gastrointestinal lesions (abdominal pain and occult blood) 
Vascular lesions (vasculitis of aorta, artery, large or small veins) 
Neuronal lesions (headache, paresis, lesions of brain and spinal cord, mental symptoms) 
Laboratory data: 1-Negative or positive pathergy test; 2-Negative or positive prick test for 
vaccine for streptococci; 3-Inflammatory responses (increase of erythrocyte sedimentation 
rate, C-reactive protein positive, neutrophilia, increase in complement activity) 
Table 1. Revised Diagnostic Criteria proposed by the Behçet’s Disease Research Committee 
of Japan in 2003 (Kurokawa & Suzuki, 2004). 
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The diagnostic system that has been suggested by the International Study Group by Behçet’s 
Disease (International Study Group for Behçet’s Disease, 1990) requires the presence of oral 
ulceration in all patients plus any 2 of the following findings: genital ulceration, typically 
defined eye lesions, typically defined skin lesions, or a positive pathery test (Table 2).  
 
Diagnostic criteria of International Study Group for Behçet’s disease 
RECURRENT ORAL ULCERATION 
Minor or major aphthous lesions or herpetiform-like lesions observed by the physician or 
patient at least three times within a 12-month period. 
PRESENCE OF TWO OTHER CRITERIA 
Recurrent genital ulceration: Observation by the physician or patient of the aphthous 
ulceration or scar is required. 
Eye lesions: The ocular disease can include anterior and/or posterior uveitis, cells in the 
vitreous, or the presence of a retinal vasculitis. 
Skin lesions: These changes, noted by the physician or patient, include erythema 
nodosum, pseudofolliculitis, and papulopustular lesions. In addition, lesions would 
include an acneiform nodule in postadolescent patients not receiving corticosteroid 
therapy. 
Positive pathergy test result:  Read by physician at 24-48 hours. 
Table 2. Modified from International Study Group for BD. Criteria for diagnosis of BD, 
Lancet 1990; 335:1078-1080. 
3.1 Oral aphthous ulcers 
The common clinical finding in Behçet’s patients is the presence of recurrent mucocutaneous 
ulcers. Oral ulcerations are usually the initial symptom, occurring in 98% of the patients 
(Okada et al., 2004). They are painful, rounded, with surrounding erythema and 
pseudomembranous covering. The lesions are 3 to 15 mm in diameter and may occur in 
clusters. The lesions may be located anywhere in the oral cavity: the lips, gums, palate, 
tongue, uvula, and posterior pharynx. They usually heal in 7-10 days without scarring, but 
scarring occurs when a particularly large ulcer heal. The lesions may recur every 5 to 10 
days, or every month, or even years apart without following any rule. The trauma to the 
oral mucosa can provoke them to appear strikingly reminiscent of the prick test (Wray et al., 
1981) and the lesions can also occur in some individuals after eating certain type of foods. 
3.2 Genital ulcers 
Genital ulcers occur in 75 to 87% of the BD patients (Smith & Shur, 2005). Genital ulcers can 
occur on the scrotum or penis in males. In females they can appear on the vulva and vaginal 
mucosa (Bonfioli & Orefice, 2005). Such ulcers can also be found on the perianal areas. 
Vulvar lesions frequently occur premenstrually (Nussenblatt, 2010). Genital lesions can be 
deep or may scar as they heal. Thus an examination of the genital region in a patient with 
suspected BD can be useful as a sign of old disease may be present. The genital lesions may 
be more painful in males.  
3.3 Skin lesions 
Skin lesions occur in 75 to 87% of the patients (Smith & Shur, 2005). Erythema nodosum like 
painful and recurrent lesions are frequently noted on the anterior surface of the leg but can 
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be also seen on the face, neck, buttocks, and elsewhere. These lesions involute without 
ulceration and scarring, in several weeks, but they may indeed leave scars.  
Acne-like lesions or folliculitis are also common dermatologic lesions. They can appear on 
the back and face.  
Forty present of patients with BD exhibit a cutaneous phenomenon termed pathergy, in 
which sterile pustules develop at sites of spontaneous or induced trauma (venipuncture, 
injection of sterile saline). This phenomenon is not pathognomonic of BD, although it is an 
important criterion that can be used for the diagnosis (International Study Group for 
Behçet’s Disease, 1990). Dermatographia, another dermatologic phenomenon of cutaneous 
hypersensitivity, can also be found in one third to one half of the patients (Zafirakis & 
Foster, 2002).  
3.4 Ocular involvement (Ocular Behçet’s disese) 
The frequency of ocular involvement in patients with BD is approximately 70%-90% 
(Atmaca, 1989; Mochizuki et al., 1996; Verity et al., 1999). The characteristic ocular 
involvement is a relapsing remitting panuveitis. Table 3 summarizes the ocular findings.  
The ocular disease manifests approximately in 2-3 years after the initial symptoms noted 
(Tugal-Tutkun et al., 2004). Morever, eye involvement may be the first presenting 
manifestation of BD in approximately 10% to 20 % of the patients (Dilsen et al., 1986). The 
mean age at onset of uveitis is around 30 years. Males are more frequently involved, had an 
earlier disease onset, and had a more severe disease. Ocular involvement in BD occurs more 
commonly and severely among Japanese and Turkish patients (Özen, 1999; Tugal-Tutkun et 
al., 2004; Tursen et al, 2003). 
The frequency of bilateral involvement ranges between 78% and 95% in in most of the series 
(Atmaca, 1989; Barra et al., 1991; Mishima et al., 1979; Tugal-Tutkun et al., 2004). Bilateral 
but asymmetric ocular inflammation is a characteristic feature (Atmaca, 1989, Bhisitkul & 
Foster, 1996). 
The ocular inflammatory episodes in BD are characteristically associated with a sudden 
severe onset of visual loss. Severity and number of repeated inflammatory attacks involving 
the posterior segment determine the extent of permanent structural changes and the 
resultant rate of irreversible visual loss. Because of that, Behçet panuveitis is a medical 
emergency, which must be treated immediately. Ocular involvement in patients with BD, 
especially posterior uveitis presence, is the primary indication of immunosuppressive 
treatment. 
In 1970, Mamo reported that 90% of the untreated patients lost their vision over a mean 
period of 3.36 years (Mamo 1970). The severity of the visual loss is also correlated with the 
duration of the disease. Ben Ezra and Cohen (BenEzra & Cohen, 1986) reported that 74% of 
eyes lost useful visual acuity 6 to 10 years after the onset of uveitis despite intensive follow-
up and treatment. In more recent studies, early and aggressive immunosuppressive 
treatment has been shown to reduce the rate of visual loss (Hamuryudan et al., 1997, Yazici 
& Ozyazgan, 1999, Kaklamani & Kaklamanis, 2001). 
3.4.1 Anterior segment 
Iridocyclitis may be isolated finding but is often generally is observed along with posterior- 
or panuveitis. The recurrent acute iridocyclitis attacks may persist for up to 2 to 3 months. 
However, the inflammation usually does not resolve completely between attacks. Mild to 
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moderate blurred vision, periorbital pain, photophobia, redness, reactive miosis, and 
lacrimation occur during acute attacks of anterior uveitis. 
Acute ciliary type of conjunctival vasodilatation and injection usually develops over a 
period of hours or days. In the slit lamp examination, there is an abundant number of 
floating cells and flare in the anterior chamber which indicates active inflammation. Small 
keratic precipitates may also be observed, typically in the lower corneal endothelium. The 
cells in the anterior chamber will move easily and slide over the corneal endothelium if the 
patient’s head is tilted.  After the cells have disappeared, persistent flare may ensue in the 
long standing cases, indicating persistent vascular damage rather than active inflammation 
that may not merit treatment. In a study from Turkey, which the laser cell flare meter was 
used and a large number of patients with BD were examined, it was suggested that those 
eyes with flare measured at ≥6 photons/s had a higher possibility of recurrence (Tugal-
Tutkun et al., 2008). 
The hypopyon may be a presentation of iridocyclitis which has been described as a 
characteristic sign. Mamo and Baghdassarian (Mamo & Baghdassarian, 1964) reported that 
hypopyon has become an uncommon finding, this apparent decline to the advent of steroid 
management in controlling inflammatory response.  It was reported that hypopyon present 
only in about one-tenth (Tugal-Tutkun et al., 2004) to one-third of BD patients (Ohno et al., 
1986; Mishima et al., 1979). However, the development of hypopyon may be provoked by 
local trauma such as cataract surgery (Kim et al., 2002, Matsuo et al., 2001) or sudden 
interruption of the treatment in patient with Behçet uveitis. The hypopyon may occur in 
other types of anterior uveitis but the hypopyon in patients with BD is typical that shifts 
with gravity as the patient changes his head position. The microhypopyon may not be 
visible to the naked eye but seen only with the slit lamp or in the angle when gonioscopic 
examination is performed, called as angle hypopyon.  
When the disease is particularly severe and long-standing, cyclitic membranes can form, 
(Inomata et al., 2003). Peripheral anterior synechia, posterior synechia and iris atrophy may 
develop during the course of repeated ocular inflammatory attacks. The presence of 
peripheral anterior synechia or iris bombe from pupillary seclusion may lead to secondary 
glaucoma. Neovascularization of the iris and secondary glaucoma may occur as a result of 
posterior segment ischemia and neovascularization. It is also an ominous sign, a 
prognosticator of poor outcome.  
Cellular infiltration also occurs in the anterior vitreous cavity behind the lens. Vitreal cells 
tend to have more restricted circulation when compared the anterior chamber as a result of 
viscosity of vitreous gel. 
Cataract formation is not unusual, due to either the inflammation or the corticosteroid 
therapy in these patients. Other less frequent anterior segment findings are episcleritis, 
scleritis, conjonctivitis, subconjunctival hemorrhage, conjunctival ulcers, filamentary 
keratitis, and corneal immune ring opacity (Colvard et al., 1977; Dursun et al., 2004; Matsuo 
et al., 2002; Zamir et al., 2003). 
3.4.2 Posterior segment 
Posterior segment involvement is a poor prognostic sign of ocular BD and is seen in up to 
93% of patients with ocular disease (Atmaca & Batıoglu, 1994). The ocular inflammatory 
episodes in BD are characteristically assosiciated with a sudden severe onset of visual loss 
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that may gradually improve with remission. Recurrent attacks of posterior segment may 
lead to severe retinal damage and irreversible visual loss (Atmaca & Batıoglu, 1994).  
The most common and universal posterior segment finding are vitritis and retinal 
perivasculitis involving both the arteries (periarteritis) and veins (periphlebitis). Active 
periphlebitis is characterized by a fluffy white haziness surrounding the vessel with patchy 
involvement and irregular outside extensions. Fluorescein angiography has been reported to 
reveal leakage from retinal vessels even in eyes without clinicallay detectable vasculitis 
(Atmaca, 1989). Vitritis is characterized by cellular infiltration and its products of the 
vitreous along with posterior segment involvement. Vitreous haze is usually severe and 
accompanied by serious posterior segment inflammation. The view of the fundus may be 
markedly obscured because of the vitreal haze. 
Occlusive vasculitic attacks of the retina are the most commonly dreaded complication of 
posterior segment involvement. Examination of the retina will show areas of hemorrhage 
and infarction in the retina. If the occlusive vasculitic attack involves the macular region, the 
visual acuity will reduce. 
The retinitis characterized by scattered superficial yellow-white solitary or multifocal 
infiltrates of the inner retina with indistinct margin, giving the retina a cloudy appearance 
with obstruction of the retinal vessels. The lesions are usually transient and heal without 
scarring. Massive deep retinal exudates involve the outer retinal layers and are associated 
with vascular obliteration. During the resolution of the posterior segment inflammation, that 
follows severe vitritis and vitreal haze, inflammatuar cells accumulate in the inferior 
preretinal area, resemble a pearl necklace. 
During the active phase, generalized vascular leakage with diffuse retinal or optic disc 
edema, optic disc hyperemia, venous engorgement, and intraretinal hemorrhages may also 
be observed. 
The most common complication of ocular BD is cystoid macular edema (CME), which 
observed in approximately in half of the patients with uveitis. It may resolve with 
appropriate treatment or if untreated progress to persistent chronic macular damage and 
sequel of CME, with structural changes after recurrences resulting in permanent visual loss. 
In some cases, it may lead to form a partial or full-thickness macular hole formation (Sheu & 
Yang, 2004). Macular ischemia due to occlusive vasculitis, scarring, degeneration with 
pigment epithelial changes, and epiretinal membrane formation may also occur (Yılmaz et 
al, 2000). 
In incomplete treated patients, gliotic inflammatory vessel sheathing, retinal ischemia, 
retinal atrophy, and retinal tear may occur (Akova et al., 1999). Disc swelling, papillitis, 
optic atrophy and papilledema due to increased intracranial pressure and dural sinus 
occlusion are the optic disc findings. In some cases, neovascularization of the iris, retina, or 
optic disc may develop. Tugal Tutkun et al. reported that intraocular inflammation is more 
frequent cause of neovascularization of optic disc than retinal vascular occlusion (Tugal-
Tutkun et al., 2006). Neovascularization may cause to vitreoretinal hemorrhage and 
tractional retinal detachment (Elgin et al., 2004; Ghate & Jorizzo, 1999; Lee, 2001; 
Nussenblatt, 1997).  
At the end stage of the ocular disease, the repeated episodes of posterior segment 
inflammation and complications cause total optic atrophy, vascular attenuation, and 
sheathing with occluded and sclerozed vessels, diffuse retinal atrophy with variable 
chorioretinal pigmentation and scarring.  
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ANTERİOR SEGMENT: 1-Iridocyclitis ± hypopyon; 2-Secondary glaucoma; 3-Secondary 
cataract 
 
Less frequent findings: 1-Episcleritis; 2-Scleritis; 3-Conjonctivitis; 4-Subconjunctival 
hemorrhage; 5-Conjunctival ulcers; 6-Filamentary keratitis; 7-Corneal immune ring opacity  
 
POSTERİOR SEGMENT: 1-Vitritis; 2-Retinal perivasculitis; 3-Retinal hemorrhage and 
infarction due to occlusive vasculitic attacks; 4-Retinitis; 5-Diffuse retinal or optic disc 
edema; 6-Optic disc hyperemia; 7-Venous engorgement; 8-Cystoid macular edema; 9-
Macular ischemia; 10-Macular scarring; 11-Pigment epithelial changes; 12-Epiretinal 
membrane formation 
 
In incomplete treated patients: 1-Vessel sheathing; 2-Retinal ischemia; 3-Retinal atrophy; 
4-Retinal tear; 5-Disc swelling; 6-Papillitis; 7-Optic atrophy; 8-Papilledema;  
9-Neovascularization of the iris, retina, or optic disc; 10-Vitreoretinal hemorrhage; 11-
Tractional retinal detachment 
 
End stage ocular disease: 1-Optic atrophy; 2-Vascular attenuation and sheathing; 3-
Diffuse retinal atrophy 
Table 3. The ocular findings. 
4. Behçet’s disease in children 
According to a French nationwide survey in 1993, the estimated prevalence of Behçet’s disease 
in children younger than 15 years of age is one in 600,000 (Kone-Paut et al., 1998). In a more 
recent study reviewing 761 patients in Turkey, almost 57% of patients with an identifiable 
diagnosis had BD, with being 10.4% juvenile onset disease (Kazokoglu et al., 2008). 
In pediatric uveitis series, the incidence of Behçet’s disease has been reported to be 0.5% to 
2.2% in countries where the disease is uncommon (Kanski & Shun-Shin, 1984; Pivetti-Pezzi, 
1996; Tugal-Tutkun et al., 1996).  By comparison, in a study from Turkey, Soylu et al. 
reported that 11% of children with uveitis had juvenile onset of BD (Soylu et al., 1997). 
The study by Tugal -Tutkun from Turkey involving 36 pediatric cases with BD reported that 
the male patients outnumbered female patients by a ratio of 2.3 to 1. Onset of uveitis was in 
late childhood. Bilateral panuveitis with retinal vasculitis and retinal infiltrates was the 
typical presentation. Uveitis was the initial manifestation of the disease in only 8.3% of the 
patients (Tugal-Tutkun & Urgancıoğlu, 2003).  
5. Pathogenesis  
The cause of BD is uncommon. It is believed to be due to an autoimmune process triggered 
by an infectious or environmental agent in a genetically predisposed individual (Pay, 2007; 
Kulaber, 2007). 
5.1 Genetics and human leukocyte antigen (HLA) typing 
The sibling ratio has been reported as 11.4-52.5% by Gül et al. Although environmental 
factors shared by families can influence familiar clustering they cannot account for this risk 
ratio, which supports a strong genetic background in BD (Gül et al, 2000). 
www.intechopen.com
Inflammation, Chronic Diseases and Cancer –  
Cell and Molecular Biology, Immunology and Clinical Bases 
 
398 
HLA-B51 allele located in the MHC (major histocompatibilty complex) locus, on 
chromosome 6p has been the most strongly associated risk factor for BD in areas along the 
Old Silk Route, with a stronger association in Turkish and Japanese patients in comparison 
to Caucasians (Verity et al, 1999).  
On the other hand, HLA-DR1 and HLA-DQw1 have been shown to be significantly 
decreased in patients with BD. This may indicate that an individual who carries these 
antigens is resistant to develop the disease. These results suggest that not only disease 
susceptibility but also resistant genes play an important role in the immunogenetic 
mechanism of BD (Numaga et al., 1988). 
5.2 Environment (Infectious agents, heat shock proteins) and self-antigens 
Individuals from endemic areas who have immigrated to areas with low prevalence of the 
disease have an intermediate risk for developing the disease, which suggest that environment, 
has some role in development of BD (Sakane et al., 1999, Zouboulis et al., 1997). 
Several microorganisms have been implicated in the pathology of BD, especially herpes 
simplex virus-1 and Streptococcus sangius (Direskeneli, 2001; Lehner, 1997; Verity et al, 1999).  
5.3 Immunohistopathology 
Immunohistopathologic studies of specimens taken from active inflammatory sites of BD 
patient support the findings of those found in the peripheral blood and indicate immune-
complex mediated disease. Necrotizing, neutrophilic (leukocytoclastic) obliterative 
perivasculitis (phlebitis) and venous thrombosis with lymphocytic and monocytic cellular 
infiltration of veins, capillaries and the arteries of all sizes, with and without fibrin 
deposition in the vessel wall, is the hallmark of BD (George et al., 1997).  
6. Diagnosis 
There is no pathognomonic or sensitive test and histopathologic finding in BD. Therefore, it 
is mainly diagnosed on the clinical grounds alone and currently relies on the recognition 
and grouping together of sufficient clinical features in a patient. The criteria defined either 
by the International Study Group of Behçet’s Disease or the Japanese Research Committee of 
Behçet’s Disease is the most commonly used criteria. Although the clinical diagnosis, some 
tests may be helpful for evaluation and diagnosis of BD. 
6.1 Fundus fluorescein angiography and indocyanine green angiography 
Fluorescein angiography and indocyanin green angiography (ICG) can provide diagnostic 
clues and may be used in the follow-up of cases with Behçet uveitis (Matsuo et al., 
1999).Vasculitic ocular changes in BD have been investigated in depth using FA. This 
technique can reveal dye leakage from retinal arteries, veins, and capillaries and also 
provides useful information about retinal vasculature. Fluorescein angiography is 
demonstrative of the retinal vasculitic lesions and reveals perivascular staining of the retina 
with vascular dye leakage of the dilated retinal capillaries during the acute stage, 
inflammation, and occlusion of the retinal vessels, even before ophthalmologic signs of 
detectable retinal perivasculitis clinically appear. The most characteristic fluorescein 
angiographic signs of Behçet’s uveitis are extensive leakage from small and large retinal and 
optic nerve vessels during early phases and staining in the late phases of the FA. 
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Eearly and profuse leakage from the optic nerve head during the early phase may be 
observed and in advanced cases, neovascularization on the optic disc and elsewhere may 
also be present. In some cases, the neovascularization on the optic disc and elsewhere may 
be overlooked during the fundus examination and it can be exposed in FA. 
Macular alterations including macular ischemia, cystoid macular edema, macular hole and 
epiretinal membrane can be seen by FA. Cyctoid macular edeme may be distinguished as 
typical late phase-pooling within the cyctic spaces with a foveal patalloid pattern.  
Atmaca reported that FA disclosed vasculitic changes in 6.3% of BD patients who had no 
abnormal finding on fundus examination (Atmaca, 1989). Fluorescein angiography is very 
important in the study and longitudinal care of patients with ocular BD. 
Fluorescein angiography does not provide adequate information about choroidal 
circulation. Indocyanine green angiography may be superior to FA by showing hyper- and 
hypo-fluorescent lesions, choroidal vessel leakage, irregular filling of the choriocapillaris 
and choriodal filling defects (Gedik et al., 2005). The ICG angiography findings described in 
the literature include optic disc hyperfluorescence, segmental staining of the retinal and 
choroidal vessels, choroidal fuzziness and hyperfluorescence, delayed perfusion of 
choriocapillaries, hypofluorescent plaques, and hyperfluorescent spots (Bozzoni-Pantaleoni 
et al., 2001; Klaeger et al., 2000).  
6.2 Ocular tests 
Optical coherence tomography may be useful in detecting and monitoring the foveal 
thickness anatomically in BD patients with CME. The laser cell flare meter may be used in 
Behçet uveitis since eyes with flare measurements is related with a higher possibility of 
recurrence (Tugal-Tutkun et al., 2008). 
6.3 Serologic studies 
The erythrocyte sedimentation rate, C-reactive protein, and other acute-phase reactants, 
such as properdin factor b and ǂ1-acid glycoprotein, may be shown elevated during the 
acute phase of BD (Özoran et al., 1996). An elevation in the level of ǃ2-microglobulin 
(Aygündüz et al., 2002) and myeloperoxidase (Accardo-Palumbo et al., 2000), generated by 
activated neutrophils, have been reported. Serum levels of several cytokines, including TNF-
ǂ, IFN-Ǆ, IL-1ǃ, IL-6, IL-8 may be also elevated.  
7. Treatment 
The primary goals of management are symptom control, early suppression of inflammation 
and prevention of end-organ damage. Even though therapy of acute disease is essential, to 
prevent or at least to decrease the number of repetitive ocular and systemic inflammatory 
episodes is important. Drugs are frequently used in combination in order to maximize the 
efficacy while minimizing side effects. The choice of medication is based on the severity of 
the disease. In general, treatment should be more aggressive whenever the following are 
present: complete BD, involvement of CNS, vascular involvement, retinal and bilateral 
involvement, male sex, and a geographic origin as the Mediterranean basin or Far East 
(Mishima et al., 1979).  
In general, the duration of treatment should be at least 6 months followed by a close 
monitoring of possible relapse afterwards; tough treatment courses may need to span a 
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number of years. Many treatment modalities have been tried in ocular BD with varying 
claims of success. For the time being, the most commonly used agents are corticosteroids, 
cytotoxic drugs, colchicine, Cyc-A and tacrolimus (FK-506). Table 4 summarizes the 
treatment modalities. 
7.1 Corticosteroids 
Systemic or topical corticosteroids have a beneficial effect on the acute ocular inflammation 
of BD but their long term use is limited as a result of significant side effects, which requires 
the simultaneous use of other is drugs.  
The application principal of corticosteroids, by whatever route, should initially be given at a 
large dose, and then tapered as quickly as possible over several weeks once the 
inflammation comes under control. Because of the inflammation may recur in reduction 
period, the corticosteroid treatment may be continued in a small dose for a long period. 
7.1.1 Topical corticosteroids for ocular disease 
Similar to other types of uveitis, in Behçet uveitis, strong steroids (prednisolone 1%, 
dexamethasone 0.1%, betamethasone) should be preferred to weaker ones. Since the 
solutions penetrates the cornea better than the suspensions or ointment, during the day the 
solutions should be preferred. The ointments may be used at bedtime. 
Topical short-acting mydriatic and cycloplegic agents (e.g., tropicamide 1%, or 
cyclopentolate 1%) along with sympathomimetics such as phenylephrine 2.5-10% should 
simultaneously added to local corticosteroids to prevent photophobia and pain by relieving 
the spasm of the ciliary muscle and pupillary sphincter, thus promoting patient comfort. 
Additionally, these agents also prevent the development of new posterior synechia 
formation in cases with iridocyclitis.  
7.1.2 Periocular corticosteroid injections 
In severe anterior uveitis and hypopyon unresponsive to frequent topical ophthalmic drops, 
periocular route (subconjunctival, anterior parabulbar sub-Tenon capsule, or trans-septal 
orbital floor injections) can also be effective. Water soluble preparations 
(methylprednisolone sodium succinate), which diffuse from the depot more rapidly, are 
short-acting, even when steroids with a prolonged biological t1/2 (dexamethasone sodium 
phosphate are used.  
Acute attacks of vitritis, intermediate uveitis, CME, and mild posterior uveitis, especially if 
unilateral, can be treated with posterior parabulbar sun-Tenon capsule corticosteroid 
injections (under topical anesthesia) with or without systemic administration. Depot agents 
should be preferred such as triamcinolone acetonide or methylprednisolone acetate to 
achieve long-lasting effect. 
7.1.3 Intravitreal corticosteroid injection 
The intravitreal triamcinolone acetonide injection may be used as an adjunctive therapy for 
the treatment of panuveitis attacks and CME in patients with BD who are unresponsive or 
intolerant to systemic medications.  
Sustained release intravitreal implants, including the fluocinolone acetonide implant and 
dexamethasone drug delivery system, offer an alternative therapy for chronic, recalcitrant 
posterior uveitis and CME. Studies in CME developed in retinal vein occlusion show 
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promising results that this treatment options may be effective in uveitis associated CME 
(Coscas et al., 2011; Haller JA et al., 2010). 
7.1.4 Systemic corticosteroids for ocular Behçet’s disease 
Acute and severe disease exacerbations of anterior uveitis, posterior, or panuveitis should 
be treated with higher dosages of systemic corticosteroid to offer a rapid response. Oral 
prednisolone 1-2 mg/kg/day given in a single morning dose after meals or intravenous 
pulse methylprednisolone 1 g/day for 3 consecutive days is preferred in concurrence with 
calcineurin inhibitors or other immunosuppressive drugs as steroid-sparing agents 
(Kaklamani & Kaklamanis, 2001, Toker et al., 2002). After remission of the disease has been 
obtained, it is gradually tapered to the maintenance dosage of 5-10 mg daily. Although oral 
corticosteroid monotherapy has palliative effect on ocular attacks, long-term treatment 
should be avoided since especially in patients with posterior segment involvement, it does 
not improve the visual prognosis and does not prevent the recurrent attacks of 
inflammation (Tugal-Tutkun et al, 2004). 
7.2 Antimetabolites 
7.2.1 Azathioprine 
In a large randomized, placebo-controlled trial, azathioprine 2.5 mg/kg/day in a dosage 
reduced the incidence, frequency, and severity of eye disease (Yazıcı et al., 1990). Early 
treatment with azathioprine is effective in controlling the attacks of posterior ocular 
inflammation and vasculitis, preventing recurrences, and improving the long-term visual 
prognosis of the disease (Greenwood et al., 1998; Nussenblatt, 1997).  
7.2.2 Mycophenolate mofetil 
Initial evidence for mycophenolate mofetil’s efficacy has been reported in animal models of 
ocular inflammation (Chanaud et al, 1995; Dick et al, 1998). Previous literature on 
mycophenolate mofetil in patients with ocular inflammation, including patients with BD, 
consists of prospective pilot studies in refractory uveitis (Kilmartin et al., 1998; Larkin G & 
Lightman 1999; Zierhut et al., 2001) and retrospective case series (Baltatzis et al., 2003; 
Choudhary et al., 2006; Doycheva et al., 2007; Greiner et al., 2002; Lau et al., 2003; Siepmann 
et al., 2006; Thorne et al., 2005).  This relatively large series makes a significant contribution 
to the literature on mycophenolate mofetil therapy for uveitis and confirms that 
mycophenolate mofetil is both effective and well tolerated. Additionally, it was reported 
that mycophenolate mofetil is an effective agent also in the treatment for uveitis in children, 
with marked steroid-sparing potential and an acceptable side effect profile (Doycheva et al. 
2007).  
There is not a prospective study on mycophenolate mofetil in patients with Behçet uveitis. 
Since mycophenolate mofetil is effective in the other type of uveitis, it may be suggested that 
this agent is cures Behçet uveitis. 
7.3 Calcineurin inhibitors  
7.3.1 Cyclosporine-A 
Cyclosporin-A (5 mg/kg/day in 2 divided doses) is effective in the treatment in most of BD 
features, especially in posterior segment disease. Cyclosporine-A, when used in combination 
with corticosteroids, has a corticosteroid-sparing effect, permitting the use of lower dosages 
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of corticosteroids. In ocular disease, it has been shown to decrease the frequency and 
severity of acute uveitis most rapidly (Binder et al, 1987; Kaklamani & Kaklamanis, 2001) 
and combined therapy with azathioprine is more effective than monotherapy with a better 
outcome in ocular disease (Sakane & Takeno, 2000; Yazici, 2002; Yazici & Özyazgan, 1999). If 
combined therapy is applied, lesser dosage of both agents is possible.  
Cyclosporine-A is a cytostatic agent, and therefore the inflammation may recur when the 
therapy is tapered or on withdrawn (rebound phenomenon). Because of that, patients 
generally need to continuous treatment for several years.  
7.3.2 Tacrolimus 
Tacrolimus (FK-506) has also been used to treat refractory posterior uveitis in BD with 
limited experience (PO 0.05-0.20 mg/kg/day b.i.d) (Kilmartin et al, 1998). In comparison 
with CycA, tacrolimus has different side effect profiles, which may be an important issue in 
the choice of this therapy (Tanabe, 2003). Tacrolimus is less frequently associated 
hyperlipidemia, hirsutizm, gingival hypertrophy, but it may induce diabetes mellitus 
(Marshall, 2004). 
7.4 Alkylating agents 
7.4.1 Chlorambucil 
Chlorambucil was the first immunosuppressive drug to be used in patients with ocular BD 
(Zafirakis & Foster, 2002). The use of this agent is not preferred in Behçet uveitis since its 
side effects and slow acting characteristic. Tabbara (Tabbara, 1983) reported long term 
results with chlorambucil that were disappointing, with 755 of eyes in patients treated with 
chlorambucil as monotherapy having visual acuity of 20/200 or less. These results could be 
explained by the fact that chlorambucil, a slow acing agent, suppresses the immune system 
slowly, which would be a disadvantage, as rapid immunosuppression is usually desirable 
for BD patients.  
7.4.2 Cyclophosphamide 
Cyclophosphamide is even more toxic than chlorambucil and it should be reserved for very 
refractory sight-threatening ocular BD patients. Cyclophosphamide has been utilized widely 
in Japan with favorable results in controlling uveitis, preventing ocular attacks, and 
maintain good visual acuity for long periods in BD patients (Hijikata & Masuda, 1978).  It 
has been shown that cyclophosphamide is superior to steroids in suppressing ocular 
inflammation in BD patients in the acute phase (Gills & Buckley, 1970; Oniki et al., 1976). 
Foster et al (Foster et al., 1991) have shown that both cyclophosphamide and chlorambucil 
were superior to Cyc-A in the management of the posterior segment manifestations of BD. 
In contrary, Ozyazgan et al reported (Ozyazgan et al., 1992) that intravenous 
cyclophosphamide was less effective than oral CycA, especially during the first 6 months of 
the treatment. 
7.5 Current concepts  
7.5.1 Interferon-α 
Clinical trials on IFN-ǂ have shown encouraging results in the treatment of severe refractory 
uveitis in BD combined with corticosteroid and immunosuppressive therapy. Initial 
treatment modalities and doses are ranging from three to nine million IU daily versus 
www.intechopen.com
 
Ocular Involvement in Behçet’s Disease 
 
403 
thrice-a-week regimen, as well as duration of IFN-ǂ2a administration and corticosteroid 
therapy tapering; vary widely, among reported studies.   
Kötter et al demonstrated in their open-label prospective study that recombinant human 
IFN-ǂ2a at a daily dosage of 6 million IU for at least 14 days is effective in ocular BD (Kötter 
et al., 2003), leading to significant improvement of visual acuity with  complete remission of 
ocular retinal vasculitis in the majority of the patients. Sight-threatening ocular disease has 
responded to IFN-ǂ2a in 92% of the cases.  
Tugal-Tutkun et al. reported that IFN-ǂ2a was effective for the treatment of Behçet’s 
patients with NVD, who were treated with intensive anti-inflammatory drugs, conventional 
immunosuppressive treatment and retinal laser photocoagulation without success (Tugal –
Tutkun et al., 2006). 
Recently a retrospective report of IFN-ǂ2a use in 7 children with corticosteroid dependent 
Behçet uveitis with clinical improvement was published, allowing corticosteroid dose 
reduction in 5 patients (Guillaume-Czitrom et al., 2007).  
7.5.2 Anti-TNF-α biological agents 
TNF-ǂ is a fundamental cytokine in the establishment and maintenance of the inflammatory 
response. At present, there are 3 TNF-ǂ inhibitors available: infliximab, are recombinant 
chimeric monoclonal antibody; adalimumab, a humanized monoclonal antibody; and the 
fusion protein human p75 TNF-ǂ receptor IgG1 etanercept (Ehrlich, 1997). 
7.5.2.1 Infliximab 
Infliximab is a human-murine chimeric anti TNF IgG1 monoclonal antibody. It binds to 
human TNF-ǂ and neutralized its activity (Saravanan & Hamilton, 2002).  
In an open label trial by Tugal-Tutkun et al., they investigated the efficacy of infliximab in 13 
BD patients with uveitis resistant the combination therapy of azathioprine, Cyc-A, and 
corticosteroids. Following 4 infusions of infliximab (5mg/kg) administrated at weeks 0, 2, 4, 
and 14, combined with azathioprine and corticosteroids, 4 patients remained attacks-free for 
22 weeks. The mean number of uveitis attacks and daily corticosteroid doses were 
significantly lower during the infusion period than the previous-treatment period (Tugal-
Tutkun et al, 2005).  
In a recent study (Tabbara et al., 2008) the outcome of retinal vasculitis in BD treated with 
conventional immunosuppressive therapy (prednisone, azathioprine, cyclosporine, or 
methotrexate) was compared to ones treated with infliximab. The authors reported that 
infliximab (5mg/kg per infusion) induced a mean remission period of 17 months in BD 
compared to a mean remission period of 5 months in patients treated with conventional 
immunosuppressive agents. These results suggest that TNF-ǂ blocking agent should be 
considered for the prevention of vision-threatening retinal vasculitis caused by BD. In this 
study 60% of the patients developed optic atrophy in the conventional therapy group 
compared to 30% in the infliximab group. Prevention of the optic nerve vasculitis by 
infliximab may be desirable in order to prevent optic atrophy. 
Retinal vasculitis in BD requires multiple infliximab infusion. Relapses have been reported 
to occur with complete cessation of infliximab infusion (Tognon et al., 2007; Toubi et al., 
2005). The clinical results obtained from these studies suggest that infiliximab is effective in 
suppressing the inflammatory episodes of retinal vasculitis and preserves visual function in 
BD patients. The exact dosage and frequency of infliximab therapy remain undetermined. 
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Table 4. The treatment modalities. 
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Etanercept is a dimeric fusion protein of the p75 kD TNF-ǂ receptor and Fc portion of 
human IgG1 (Maini & Taylor, 2000). It is produces by recombinant DNA technology, has a 
good tolerability, and is administered by subcutaneous injection (Thomas-Golbanov & 
Sridharan, 2001). A recent experimental study from Turkey has demonstrated that 
etanercept has a definite effect on the treatment of endotoxin-induced uveitis in rats 
(Avunduk et al., 2004). Clinically, beneficial effects have been observed with etanercept in 
maintaining visual acuity in BD patients with refractory uveitis, although the effect was not 
sustained in the post-treatment follow-up (Melikoglu et al., 2002). 
7.5.2.3 Adalimumab 
This agent has maintained disease remission in 3 patients with uveitis with no recurrences 
and stable visual acuity during the follow-up after whom being switched from infliximab to 
adalimumab (Mushtaq et al., 2007). Van Laar Jam et al reported that 6 patients with 
refractory disease (2 of them uveitis) were treated with adalimumab (with or without other 
therapies) and showed clinical improvement (Van Laar et al., 2007). A recent study 
involving 11 patients reported that adalimumab has been shown to improve visual acuity 
and also to have a corticosteroid and immunosuppressive sparing effect. It can induce and 
maintain sustained remission of the disease (Bawazeer et al., 2010). 
7.6 Management of ocular complications 
Cataract formation is especially common, both because of the recurrent inflammation and as 
a consequence of the steroid treatment. Cataract surgery should be delayed until uveitis has 
been quiescent for at least 3 months. Perioperative anti-inflammatory therapy, including 
topical, periocular, intracamaral, intravitreal, or even systemic corticosteroid, should be 
aggressively employed with intensive pre-, intra and post-surgery. Immunosuppressive 
drugs should be continued during the pre- and postoperative period. During the surgery 
minimum trauma should be given to the eye and minimal corneal incision should be 
performed. Complete removal of cortical material is important and a posterior chamber 
intraocular lens should be placed into the capsular bag. Intense fibrinoid reaction may still 
develop postoperatively. Nd:YAG laser capsulotomy may be needed in many cases for 
secondary posterior capsule opacifications which are frequently seen in the eyes with 
uveitis. With appropriate preoperative and postoperative suppression of inflammation, 
phacoemulsification and intraocular lens implantation are safe procedures leading to visual 
improvement in patients with BD without preexisting fundus lesions (Berker et al., 2004; 
Ciftci & Ozdemir, 1996; Gungor et al., 2008).  
Secondary and neovascular glaucoma may be responsible for vision loss in BD patients. 
Initial therapy with topical and systemic antiglaucoma medications may not suffice. 
Secondary glaucomas in BD with or without pupillary block and angle-closure glaucoma, if 
present, may be treated with Nd:YAG-laser iridotomy or surgical peripheral iridectomy, 
diode-laser cyclodestruction, trabeculectomy with antimetabolites or aqueous drainage 
implants, as indicated (Elgin et al., 2004; Yalvaç et al., 2004). Cyclocryotherapy may be 
indicated for neovascular glaucoma and enucleation for cosmetic reasons or painful eyes. 
Pars plana vitrectomy may be indicated in case of epiretinal membrane, macular hole, or 
vitreous hemorrhage along with retinal photocoagulation in cases of retinal tears. Retinal 
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detachment is therefore common in the later stages of the disease. Phthisis bulbi with or 
without iris neovascularization usually follows retinal detachment. 
Development of retinal and optic disc neovascularization is a major complication of the 
repeated attacks on the retinal vasculature. This neovascularization is attributed to the BD 
vasculopathy leading to retinal hypoxia. Meticulous evaluation of retina is very important 
for the early diagnosis of neovascularization. Control of the inflammation is important; 
additionally laser photocoagulation of the ischemic area is helpful. Intravitreal anti- vascular 
endothelial growth factor agent might be applied. 
8. Prognosis 
BD has a variable course characterized by relapses and remissions. Prognosis depends on 
the clinical involvement. Loss of visual acuity and neurological disease are major causes of 
morbidity and mortality.  
Prognosis of BD improved in the last decade due to the use of modern therapy modalities, 
including IFN-ǂ and anti TNF-ǂ blockers, and a more aggressive treatment strategy. Despite 
modern treatment, the disease still carries a poor visual prognosis with one-quarter of the 
patients blind (Kump et al., 2008; Yoshida et al., 2004). 
Sakomato et al (Sakamoto et al., 1995) did try to determine prognostic factors for visual 
outcome. They concluded that skin lesions, arthritis and posterior uveitis attacks were 
linked to loss of vision, whereas female sex, disease free interval, and anterior attacks were 
related to retention of vision. Demiroğlu et al (Demiroglu et al., 1997) reported that age of 30 
years or less, male sex, vascular thrombosis, and CNS involvement were risk factors for 
ocular disease. 
Recently, Kaçmaz et al. conducted a study to estimate the risk of structural ocular 
complications and loss of visual acuity in cases with BD. They reported that loss of visual 
acuity and ocular complications might occur in patients with ocular inflammation associated 
with BD, even with aggressive therapy. Ongoing inflammation during follow-up, presence 
or occurrence of posterior synechia, hypotony, and elevated IOP were associated with an 
increased risk of loss of visual acuity (Kaçmaz et al., 2008). 
9. Conclusions 
Behçet’s disease is a multi-system inflammatory disease, characterized by relapsing 
inflammation. Although intraocular inflammation may involve anterior or posterior 
segment, the hallmark of BD is the presence of panuveitis and vasculitis, and the sequela of 
the posterior segment inflammation appears to be sight-threatening. Corticosteroids are 
used to control acute inflammation, but have little effect in controlling recurrences. 
Conventional immunosuppression agents (most frequently azathioprine and Cyc-A) are the 
most frequently used agents in preventing recurrences in BD. However conventional 
immunosuppressive agents may take several weeks to show significant clinical effect and 
induce remission. In cases resistant to these agents, IFN-ǂ2a and anti-TNF agents (esp. 
infliximab) give promising results in the treatment of Behçet uveitis. However, controlled 
randomized studies are necessary to determine the optimum doses and duration of therapy 
and specify the role of these immunomodulatary agents in the therapeutic regimen. In 
addition to this, new treatment agents are still needed. 
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